Research programme: anti-COVID-2019 monoclonal antibodies - Vanderbilt University Medical Center/National Resilience
Latest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator Vanderbilt University Medical Center
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 27 Mar 2020 Twist Bioscience entered into collaboration agreement with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19